At a glance
Effects
- Lean muscle retention: Promotes muscle preservation during calorie-restricted or cutting phases by increasing protein synthesis and maintaining positive nitrogen balance [2].
- Dry, quality gains: Does not aromatise to estrogen, so gains are lean and free of water retention or bloating [3].
- Fat loss / recomposition: Non-estrogenic, low-androgenic profile makes it a preferred compound for cutting cycles; some evidence it supports fat oxidation in a caloric deficit [5].
- Enhanced endurance: Stimulates erythropoiesis (red blood cell production), increasing oxygen-carrying capacity and supporting training volume [2].
- Mild androgenic side-effect burden: Lower androgenic potency relative to testosterone means reduced risk of aggression, severe acne, and accelerated hair loss compared to harsher AAS [6].
Anabolic-androgenic steroid (AAS), DHT derivative
~6 hours (oral acetate) — requires daily dosing
Oral (tablet)
Up to 4–6 weeks (urine)
DEA Schedule III controlled substance
About Methenolone Acetate
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Methenolone Acetate (brand name Primobolan) is an oral anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT), medically indicated for anemia due to bone marrow failure [1]. In performance and physique contexts it is used primarily for lean muscle retention, fat-loss ("cutting") cycles, and body recomposition with a relatively mild side-effect profile compared to stronger AAS [5].
How it works
Methenolone binds directly to androgen receptors in muscle, fat, and reproductive tissue with moderate affinity without requiring conversion to a more potent metabolite [4]. Receptor activation promotes protein synthesis and nitrogen retention in muscle cells, creating the anabolic (positive nitrogen-balance) environment needed for muscle preservation and growth [2]. Because it is a DHT derivative, it cannot be aromatised by the aromatase enzyme, so it produces no estrogen-related effects such as water retention or gynecomastia [3]. Oral bioavailability is achieved via a 1-methyl group (C1-methylation) rather than the hepatotoxic C17α-alkylation used by most other oral AAS, though the acetate form still carries a real, if lower, liver burden [1][6].
Risks & side effects
Most important: All AAS, including Methenolone Acetate, suppress the hypothalamic-pituitary-testicular (HPT) axis, reducing LH and FSH and cutting endogenous testosterone production; without post-cycle therapy (PCT), this suppression can persist for weeks to months after stopping use [7][8]. Additionally, the oral acetate form carries a genuine, if comparatively lower, risk of liver stress and adverse changes to the HDL/LDL cholesterol balance, which may accelerate cardiovascular disease over time [6][9].
Common
Serious
- Cardiovascular strain: raised blood pressure, increased LVH risk, and potential myocardial infarction risk with chronic use [9]
- Prolonged hypogonadism if PCT is omitted or inadequate [8]
- Virilisation in women: voice deepening, clitoral enlargement, facial hair [5]
- Liver fibrosis or hepatocellular damage with high-dose or prolonged oral use [6]
- Psychiatric changes (depression, irritability) during use or after cessation [10]
Safety & harm reduction
- Pregnancy or breastfeeding — AAS cause foetal virilisation
- Prostate or breast cancer (androgen-sensitive tumours)
- Pre-existing significant hepatic impairment
- Paediatric use — premature epiphyseal closure and virilisation risk
- Diagnosed cardiovascular disease or uncontrolled hypertension
- Hypersensitivity to methenolone or any excipient
- Liver function tests (ALT, AST, bilirubin) at baseline and every 6–8 weeks during oral use
- Full lipid panel (HDL, LDL, triglycerides) — baseline and on-cycle
- Blood pressure monitoring throughout cycle
- Haematocrit / haemoglobin (erythropoiesis stimulation)
- Total and free testosterone, LH, FSH — for suppression tracking and PCT guidance
- PSA in males over 40
- Anticoagulants (e.g. warfarin): AAS may potentiate anticoagulant effect — dose adjustment and INR monitoring required [3]
- Antidiabetics / insulin: AAS can alter glucose tolerance; hypoglycaemia risk [3]
- Ciclosporin: AAS may enhance ciclosporin levels and toxicity [3]
- Levothyroxine: may alter thyroid-binding globulin and thyroid function test results [3]
- Neuromuscular blocking agents: resistance to effect may occur [3]
- Oral AAS cycle: include liver-support supplements (e.g. TUDCA or NAC) throughout the cycle
- PCT with SERMs (e.g. Nolvadex/Clomid) is strongly advised after any cycle >4–6 weeks to restore HPT axis function [7][8]
- Cardiovascular support: maintain active cardio training and a low-saturated-fat diet to partially offset lipid changes
- Do not combine with other hepatotoxic oral AAS or hepatotoxic drugs
- Cycle length: community harm-reduction guidance suggests keeping oral cycles ≤8–10 weeks to limit cumulative liver burden
Dosage context
Commonly reported (non-prescription, community-observed) oral doses for men are 50–100 mg/day, typically split across two daily administrations to compensate for the short (~6-hour) half-life [4][5]. Female community-reported doses are substantially lower; even modest doses carry virilisation risk and should be approached with extreme caution [5]. These figures are commonly reported in harm-reduction literature, not a clinical prescription — individual tolerance and cycle length materially alter risk. Authoritative dosage guidance is limited given the drug's largely discontinued medical status.
Sources
- 1.Wikipedia — Metenolone acetate
- 2.Synapse/PatSnap — Mechanism of Metenolone Acetate
- 3.NCATS Inxight Drugs — Methenolone Acetate
- 4.HighPeptides — Primobolan (Methenolone) Guide 2026
- 5.Wikipedia — Metenolone (parent compound)
- 6.BenchChem — Methenolone Acetate research profile
- 7.Swolverine — Methenolone comprehensive guide
- 8.Swolverine — Primobolan dosage guide
- 9.ChemicalBook — Methenolone Acetate side effects
- 10.INCHEM / WHO — Methenolone PIM 907
- 11.European Review — Hepatotoxicity of illicit AAS (peer-reviewed)
- 12.PMC — PCT and AAS withdrawal symptoms survey
- 13.Synapse/PatSnap — Side effects of Metenolone Acetate
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.